Latest Breaking News On - Prnewswire novo holdings - Page 5 : comparemela.com

Share this article Share this article COPENHAGEN, Denmark, May 20, 2021 /PRNewswire/ Novo Holdings today announced that it has co-led the oversubscribed CHF 100 million (approximately USD 110 million) Series C financing in Numab Therapeutics AG (Numab) alongside HBM Partners, with participation from new investors Forbion via its Forbion Growth Opportunities Fund, Cormorant Asset Management, BVF Partners L.P., RTW Investments L.P., fund and accounts under the management of BlackRock, Octagon Capital Advisors, and existing investors. Numab is a clinical stage biopharmaceutical company developing next-generation multispecific antibody-based immunotherapies for cancer and inflammation. Nanna Lüneborg, Partner at Novo Ventures, will join Numab s Board of Directors.

David urechForbion growth opportunities fundPrnewswire novo holdingsNovo holdingNovo holdingsNumab therapeuticsCormorant asset managementOctagon capital advisorsInovo venturesBoard directorHuman serum albuminகருப்பு பாறைநோவோ வைத்திருத்தல்நோவோ ஹோல்டிங்ஸ்கர்மரண்ட் சொத்து மேலாண்மைநோவோ முயற்சிகள்